Quad's vincristine sulfate
Executive Summary
Par Pharmaceutical's subsidiary received FDA approval for the oncolytic agent in 1 mg/ml injectable in 1, 2, and 5 mg vials. Quad said it will launch the product, the first generic form of Lilly's Oncovin, the week of May 13. Par said the firm also received approval for a preservative-free form of vincristine.